GNMSF
GENMAB A/S
$249.45
0.00%
No data for this timeframe.
Vol
SEC Reports10
Recent Activity
May 29, 2026
SEC
This 6-K filing reports a routine insider sale by Board member Michael Kavanagh, who sold 526 shares at DKK 1,734.75 eac
6-K — Impact 2/10
May 13, 2026
SEC
Genmab filed its updated Articles of Association as a 6-K, reflecting routine corporate governance updates including aut
6-K — Impact 2/10
May 12, 2026
SEC
Genmab announced a nominal capital increase of 2,346 shares (0.004% of share capital) from employee warrant exercises, r
6-K — Impact 1/10
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: Epcoritamab (Phase 2)
Trial: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large
Jun 26, 2024
Event
EPKINLY
Supplemental Approval — Efficacy — EPCORITAMAB-BYSP — INJECTABLE — SUBCUTANEOUS
Analyst Ratings
5Strong Buy
14Buy
4Hold
1Sell
1Strong Sell
Latest Reports
NEUTRAL
6-K
2/10
This 6-K filing reports a routine insider sale by Board member Michael Kavanagh, who sold 526 shares at DKK 1,734.75 eac
May 29, 2026
NEUTRAL
6-K
2/10
Genmab filed its updated Articles of Association as a 6-K, reflecting routine corporate governance updates including aut
May 13, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
10 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 10 neutral. Avg impact: 2.2/10.
NEUTRAL
6-K
2/10
This 6-K filing reports a routine insider sale by Board member Michael Kavanagh, who sold 526 shares
May 29, 2026
NEUTRAL
6-K
2/10
Genmab filed its updated Articles of Association as a 6-K, reflecting routine corporate governance u
May 13, 2026
NEUTRAL
6-K
1/10
Genmab announced a nominal capital increase of 2,346 shares (0.004% of share capital) from employee
May 12, 2026
NEUTRAL
6-K
2/10
Orbis Investment Management Limited disclosed a 5.08% passive stake in Genmab A/S, up from the previ
May 8, 2026
NEUTRAL
6-K
3/10
Genmab AS filed an updated version of its Articles of Association, incorporating amendments made on
Apr 17, 2026
NEUTRAL
6-K
2/10
Genmab AS reduced its share capital by canceling 1.9 million treasury shares, decreasing the total n
Apr 17, 2026
NEUTRAL
6-K
4/10
Genmab announced Q1 2026 worldwide net sales of DARZALEX (daratumumab) at $3.964 billion, with $2.20
Apr 14, 2026
NEUTRAL
6-K
2/10
Genmab disclosed routine insider transactions involving the vesting of restricted stock units for si
Apr 1, 2026
NEUTRAL
6-K
2/10
Genmab A/S announced that Orbis Investment Management Limited has acquired a 5.01% stake in the comp
Apr 1, 2026
NEUTRAL
6-K
2/10
Genmab AS disclosed that Orbis Investment Management Limited has reduced its stake to 4.99% of the c
Mar 30, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 76% buy across 25 analysts — 5 strong buy, 14 buy, 4 hold, 1 sell, 1 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $7.0B | 17.3% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $7.3B | 10.7% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $27.6B | 17.5% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $32.4B | 17.3% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 14 | 4 | 1 | 1 | 76% | |
| May 1, 2026 | 5 | 14 | 6 | 1 | 1 | 70% | |
| Apr 1, 2026 | 5 | 12 | 8 | 1 | 1 | 63% | |
| Mar 1, 2026 | 5 | 11 | 8 | 1 | 1 | 62% | |
| Feb 1, 2026 | 4 | 12 | 8 | 1 | 1 | 62% | |
| Jan 1, 2026 | 3 | 13 | 9 | 1 | 1 | 59% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
Clinical Trial
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Phase Phase 2 — TERMINATED
May 14, 2026
Clinical Trial
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Phase Phase 2 — TERMINATED
May 13, 2026
Clinical Trial
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Phase Phase 2 — TERMINATED
Apr 1, 2026
Clinical Trial
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Phase Phase 2 — TERMINATED
Apr 1, 2026
Clinical Trial
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: Epcoritamab (Phase 2)
Trial: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
Sponsor: Genmab
Phase: Phase 2 |
Jun 26, 2024
FDA
EPKINLY
Supplemental Approval — Efficacy — EPCORITAMAB-BYSP — INJECTABLE — SUBCUTANEOUS